STOCK TITAN

Heartbeam Inc - BEAT STOCK NEWS

Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.

HeartBeam Inc (BEAT) pioneers portable cardiac monitoring solutions through its credit card-sized ECG device and AI-driven diagnostic platform. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in remote cardiology technology.

Access authoritative reporting on regulatory milestones, clinical study results, and strategic partnerships shaping the future of telehealth diagnostics. Our curated collection includes earnings reports, product launch announcements, and peer-reviewed research validations, including studies conducted with Harvard Medical School faculty.

Key updates cover developments in Vector ECG technology, FDA clearance progress, and AI algorithm enhancements that improve cardiac event detection accuracy. Bookmark this page to stay informed about innovations bridging hospital-grade diagnostics with at-home healthcare solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.68%
Tags
none
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) announced its acquisition of LIVMOR’s assets, including the FDA-cleared Halo+™ Atrial Fibrillation Detection System, enhancing its remote monitoring capabilities. The partnership with Evolve Manufacturing aims to develop the HeartBeam AIMIGo 12-Lead electrocardiogram device, with initial market testing slated for Q4 2023 post-FDA clearance. The company received European patents protecting its technology, facilitating expansion. Financial results show a net loss of $3.7 million for Q4 2022, up from $2.1 million a year prior, with cash reserves at $3.6 million. Management projects further advancements in FDA submissions in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.63%
Tags
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has acquired substantially all assets of LIVMOR, a digital health solutions company, enhancing its capabilities in remote cardiac monitoring. This acquisition includes the FDA-cleared Halo+™ Atrial Fibrillation Detection System, the first prescription wearable for continuous monitoring of cardiac rhythms. Founded in 2016, LIVMOR's technology has been deployed in the VA Healthcare System in Dallas, Texas. The strategic move is expected to integrate LIVMOR's cloud-based software with HeartBeam's existing solutions, potentially improving patient outcomes and reducing healthcare costs. Financial terms remain undisclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags

FAQ

What is the current stock price of Heartbeam (BEAT)?

The current stock price of Heartbeam (BEAT) is $1.81 as of April 29, 2025.

What is the market cap of Heartbeam (BEAT)?

The market cap of Heartbeam (BEAT) is approximately 51.3M.
Heartbeam Inc

Nasdaq:BEAT

BEAT Rankings

BEAT Stock Data

51.26M
26.15M
23.17%
7.89%
0.68%
Health Information Services
Surgical & Medical Instruments & Apparatus
Link
United States
SANTA CLARA